A Retrospective Analysis of Micafungin Prophylaxis in Children Under 12 Years Undergoing Chemotherapy or Hematopoietic Stem Cell Transplantation
A low rate of breakthrough IFI was seen with micafungin prophylaxis that is consistent with prior published adult hematopoietic stem cell transplantation studies. Micafungin was well tolerated, with liver function test elevations being transient in most cases and thought to be related to alternative factors.
Authors
- Breana K. Goscicki
- Audrey Mauguen (ORCID: https://orcid.org/0000-0003-3236-6093)
- Shirley Qiong Yan
- Nina Cohen (ORCID: https://orcid.org/0000-0002-5726-8986)
- Sherry Mathew (ORCID: https://orcid.org/0000-0001-5689-8233)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Pfizer (United States) (US)
- Children's Hospital of Pittsburgh (US)
Publication Details
- Journal
- The Journal of Pediatric Pharmacology and Therapeutics
- Published
- 2024-08-01
- DOI
- https://doi.org/10.5863/1551-6776-29.4.379
- Citations
- 1
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.39